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Introduction: The enhanced Type 2 helper (Th2) immune response is responsible for 41 
the pathogenesis of allergic asthma. To suppress the enhanced Th2 immune response, 42 
activation of the Th1 immune response has been an alternative strategy for anti-asthma 43 
therapy. In this context, effective Th1-inducing adjuvants that inhibit the development 44 
of allergic asthma but do not flare the side effects of the primary agent are required in 45 
clinical treatment and preventive medicine.  46 
Objective: In this study, we aimed to determine the regulation of the Th2 type immune 47 
response in asthma by a novel immunostimulatory oligodeoxynucleotide (ODN) derived 48 
from Cryptococcus neoformans, termed ODN112, that contains a cytosine-guanine 49 
(CG) sequence but not canonical CpG motifs. 50 
Methods: Using an ovalbumin (OVA)-induced asthma mouse model, we assessed the 51 
effect of ODN112 on prototypical asthma-related features in the lung and on the 52 
Th1/Th2 profile in the lymph nodes and lung of mice treated with ODN112 during 53 
sensitization.  54 
Results and Conclusion: ODN112 treatment attenuated asthma features in mice. In the 55 
bronchial lymph nodes of the lungs and in the spleen, ODN112 increased Interferon 56 
(IFN)-γ production and attenuated Th2 recall responses. In dendritic cells (DCs) after 57 
allergen sensitization, ODN112 enhanced cluster of differentiation (CD)40 and CD80 58 
expression, but did not alter CD86 expression. Interleukin (IL)-12p40 production from 59 
DCs was also increased in a Th2-polarizing condition. Our results suggest that ODN112 60 
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is a potential Th1-inducing adjuvant during Th2 cell differentiation in the sensitization 61 




Recent developments in clustering analysis report that the major clinical 64 
phenotype of asthma that is associated with eosinophilia presents as the type 2 65 
(Th2/T2)-high inflammatory “allergic asthma” endotype [1]. The enhanced Th2 immune 66 
response is mediated by antigen-specific Th cells and type 2 innate lymphoid cells that 67 
produce Th2 cytokines, such as Interleukin (IL)-4, IL-5, and IL-13 [1]. Thus, Th2 68 
cytokines play a critical role in the induction of type 2 inflammation in allergic asthma 69 
such as eosinophilia, allergen-specific IgE production, and IgE-mediated mast cell and 70 
basophil degranulation [1]. 71 
The conceptual balancing of Th1/Th2 as a therapeutic strategy for the clinical 72 
remission of allergic asthma led to the use of Th1-inducing adjuvants in realistic 73 
anti-asthma therapy [2]. Administration of live- or heat killed-bacteria, such as 74 
Mycobacterium bovis [3], Francisella tularensis [4], or Listeria monocytogenes [5] 75 
suppresses the allergic Th2 responses through the induction of IFN-γ mediated Th1-like 76 
immune response. Pathogen-associated molecular patterns derived from microbes, such 77 
as cell wall components and purified proteins of Mycobacteria [6], high levels of 78 
endotoxins [7], or immunostimulatory (ISS) oligodeoxynucleotide (ODN) [8] interact 79 
with pattern recognition receptors of immune cells, leading to a robust in vivo Th1 80 
response.  81 
Toll-like receptor (TLR)9, a member of the TLR family, is expressed inside 82 
immune cells such as B cells and dendritic cells (DCs) of humans and mice, and 83 
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recognizes the unmethylated CpG DNA of bacteria and viruses [9]. TLR9 agonists have 84 
enormous potential as Th1-inducing adjuvants in protection against allergic disease [10]. 85 
TLR9 activation by specific ISS-DNA sequences rich in non-methylated CpG motifs 86 
such as 5’-purine-purine-cytosine-guanine-pyrimidine-pyrimidine-3’ (CpG-ODN) 87 
induces a strong Th1 immune response with Interferon (IFN)-γ induction [11]. The 88 
immunologic activities of CpG-ODN are dependent on the content of their palindromic 89 
hexamer [8]. Of the three major classes of CpG-ODN, the B-class CpG-ODN strongly 90 
induces DC maturation [12] and attenuates Th2 immune response through IL-12 91 
induction followed by IFN-γ production [13]. In some clinical trials, the B-class 92 
CpG-ODN lead to Th2 immune response attenuation by balancing Th1/Th2 in allergy 93 
[14]. However, concerns exist about the undesirable side effects of repeated 94 
administrations of CpG-ODNs with a phosphorothioate backbone [15]. Heikenwalder et 95 
al. reported that daily injection of CpG-ODN suppressed follicular dendritic cells and 96 
germinal center B lymphocytes in lymphoid follicles, and reduced primary humoral 97 
immune responses and immunoglobulin class switching [15]. Therefore, there is a need 98 
to explore more practical Th1-inducing adjuvants that can inhibit the development of 99 
allergic asthma, without inducing side effects. 100 
Cryptococcus neoformans is an opportunistic fungal pathogen, frequently 101 
associated with fatal meningoencephalitis in immunocompromised patients such as 102 
those with acquired immunodeficiency syndrome and organ transplantation [16]. The 103 
outcome of C. neoformans infection is dependent on the balance between Th1 and Th2 104 
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immune responses in vivo. A predominance of Th1 over Th2 type immune response lead 105 
to protection against C. neoformans infection [17], while Th2 immune predominance 106 
such as eosinophilia or elevated serum IgE increased susceptibility to cryptococcosis 107 
[18, 19]. Excess polarization of Th1 or Th2 might be associated with undesired effects 108 
in patients. In this context, adjuvants that have controllable and optimized effects on the 109 
Th1/Th2 balance for asthma prevention are required. Namely, ODNs having certain 110 
Th1-inducing activity as well as an unmodified backbone in order to not to leave it in 111 
vivo more than necessary, could be a viable candidate. 112 
In host defense against C. neoformans, the role of TLR9 in detecting the 113 
pathogenic DNA plays an important role in fungal clearance from the lungs through 114 
IL-12p40 induction [20]. A previous study by our group demonstrated that the presence 115 
of a certain CpG-independent mechanism is involved in TLR9-mediated immune 116 
activation by C. neoformans DNA [20]. We also demonstrated that a 24-base ODN 117 
fragment (termed ODN112) with an unmodified backbone, of the URA5 gene that 118 
encodes a virulent component of C. neoformans induces a robust IL-12p40 synthesis by 119 
DCs in a TLR9 dependent manner [21]. These evidences increase the possibility that a 120 
novel TLR9 agonist derived from C. neoformans, ODN112, could be a candidate 121 
Th1-inducing immune adjuvant for inhibiting Th2 in allergic asthma. In this study, we 122 
explore the potent inhibitory effect of ODN112 on allergic airway inflammation using 123 
the ovalbumin (OVA)-induced asthma mouse model.  124 
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Materials and Methods 125 
Mice: Female C57BL/6 mice (CLEA Japan, Inc.; Osaka, Japan) were maintained in 126 
specific pathogen-free conditions at the Institute for Animal Experimentation, Tohoku 127 
Medical and Pharmaceutical University (Sendai, Japan).  128 
Oligonucleotides: ODN112, a 24-base oligodeoxynucleotide fragment of the URA5 129 
gene from C. neoformans, designated Cap67 (a kind gift from Stuart M. Levitz, Boston 130 
University, Boston, MA), and a prototypic phosphorothioated-CpG1826 131 
oligodeoxynucleotide (CpG-ODN), as shown in Table 1, were synthesized and purified 132 
by high-performance liquid chromatography at Hokkaido System Science (Sapporo, 133 
Japan). A modified ODN112 derivative in which CG was replaced by GC within 134 
5’-GTCGGT-3’, termed ODN112GC, was also synthesized at Hokkaido System 135 
Science (Table 1). In the present study, CpG-ODN was used as a positive control for the 136 
treatment. In addition, ODN112GC was used as a negative control of the treatment with 137 
ODN112. We evaluated the effects of the treatment with ODNs, compared to vehicle 138 
treatment. 139 
Sensitization and antigen challenge: Six-week old mice were sensitized with 140 
intraperitoneal injections of 8 µg OVA (Grade V, Sigma-Aldrich, St Louis, MO) and 141 
oligonucleotides adsorbed with 4 mg aluminum hydroxide (Wako Pure Chemical 142 
Industries, Ltd., Osaka, Japan) in 500 µL saline, on days 0 and 5. On day 26, mice were 143 
challenged with aerosolized OVA (0.5% in saline) for 1 h on two occasions, 4 h apart 144 
[22]. The experimental design of the study, including the time points of sensitization, 145 
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inhalation, and sampling, are indicated in Figure 1. 146 
Measurement of airway hyperresponsiveness: Lung resistance was measured for 3 min 147 
under each condition by the Resistance and Compliance System (Finepoint; Buxco 148 
Electronics, Sharon, CT) [23]. The conditions analyzed were baseline response to 149 
aerosolized saline and increasing doses (1.25 mg/mL, 2.5 mg/ml, 5 mg/ml, 10 mg/ml, 150 
20 mg/mL) of acetyl-β-methylcholine (methacholine; Sigma-Aldrich). 151 
Measurement of OVA-specific antibodies: Serum levels of OVA-specific IgE and IgG1 152 
Ab were measured by ELISA [24]. In brief, microtiter plates (Nunc A/S Roskilde; 153 
Thermo Fisher Scientific, Denmark) were coated with 10 μg/mL OVA in 0.05 M 154 
bicarbonate buffer (pH 9.6) and incubated overnight at 4 °C. After blocking with PBS 155 
containing 1% bovine serum albumin (BSA), serum samples diluted with 1% BSA PBS 156 
were added to the well. Pooled serum of sensitized C57BL/6 female mice was used as a 157 
reference. Horseradish peroxidase-conjugated goat anti-mouse IgE (Bethyl Laboratories, 158 
Owing Mills, MD) and IgG1 Ab (Southern Biotechnology Associates, Birmingham, AL) 159 
diluted to 1:2,500 were used as detection antibodies. The concentrations of IgE and 160 
IgG1 were determined based on the absorbance at 450 nm. 161 
Preparation of the BAL fluids: Bronchoalveolar lavage (BAL) fluids were prepared as 162 
previously described [25]. Briefly, BAL samples collected on day 5 after OVA 163 
inhalation (with 2  0.25 mL chilled PBS through a cannula inserted in the trachea) 164 
were centrifuged at 450  g for 10 min at 4 °C. Cells (2  105) were stained with 165 
Diff-Quick solution (Sysmex Co., Kobe, Japan), and cell differential percentage was 166 
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determined by counting a minimum of 200 cells by light microscopy. 167 
Lung histology: Lungs were isolated from mice at the indicated time points after OVA 168 
challenge, fixed in 10% buffered formalin, dehydrated, and embedded in paraffin. 169 
Sections were cut 4-μm-thick, and then stained with hematoxylin and eosin, periodic 170 
acid–Schiff (PAS), or Masson’s trichrome staining. Eosinophil counts were estimated as 171 
the number of eosinophils per square millimeter, closely surrounding the bronchus. 172 
Mucin production was estimated as the proportion of PAS-positive cells in the total 173 
airway epithelium of bronchioles by PAS-staining. The proportions of collagen fibers in 174 
peribronchial regions were evaluated by Masson’s trichrome staining. The number of 175 
eosinophils and PAS-positive cells were calculated in each of the five random 176 
bronchioles in three lung sections from each mouse [26]. 177 
Preparation of the lung homogenate: For reverse transcription (RT)-PCR, the entire 178 
lungs were excised from sensitized mice one day after OVA challenge and homogenized 179 
in buffer RLT (QIAGEN, Valencia, CA) supplemented with 1% 2-mercaptoethanol. For 180 
cytokine assay, the entire lungs were excised one day after OVA inhalation and 181 
homogenized in chilled 0.1% Triton-X PBS with 1% protease inhibitor (Sigma-Aldrich). 182 
After centrifugation at 15,000  g for 15 min at 4 °C, the supernatants were stored at 183 
-80 °C [25]. 184 
RT-PCR analysis: Total RNA was extracted from entire lung homogenates using a 185 
ReliaPrep RNA cell miniprep system (Promega Corporation, Madison, WI) or RNeasy 186 
mini kit (QIAGEN, Valencia, CA). First-strand cDNA was synthesized using the 187 
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PrimeScript RT reagent kit with gDNA Eraser (TaKaRa Bio Inc., Otsu, Japan). 188 
Real-time RT-PCR was performed using gene-specific primers and Power SYBR Green 189 
PCR Master Mix (Applied Biosystems, Foster City, CA) and a StepOnePlus Real-Time 190 
PCR system (Applied Biosystems) [25]. The primer sequences used for amplification 191 
are shown in Supplementary Table 1. The expression levels of target genes and 192 
hypoxanthine-guanine phosphoribosyltransferase (Hprt) as a reference gene were 193 
calculated for each sample using the reaction efficiency, as determined by performing 194 
amplifications using standards.  195 
Measurement of cytokine concentration: Levels of IL-4, IL-5, IL-13, and IFN-γ were 196 
assayed using ELISA kits (eBioscience, San Diego, CA). The detection limits were 4 197 
pg/mL for IL-4, IL-5, and IL-13; and 15 pg/mL for IFN-γ. Total protein levels of the 198 
lung homogenates were assayed using a detergent-compatible protein assay kit 199 
(Bio-Rad Laboratory, Hercules, CA). The cytokine and chemokine concentrations in the 200 
lung were adjusted for the protein level of each lung [25]. 201 
Preparation of lung white blood cells: Mice were sacrificed one day after OVA 202 
challenge. Pulmonary leukocytes were prepared as previously described [27]. Briefly, 203 
the lung vascular bed was flushed with 5 mL chilled saline that was injected into the 204 
right ventricle. The entire lungs were teased through a 40-µm cell strainer (BD Falcon, 205 
Bedford, MA) and incubated in RPMI 1640 medium (Nakarai Tesque, Kyoto, Japan) 206 
with 10% fetal calf serum (FCS; Thermo Fisher Scientific, Waltham, MA), 100 U/mL 207 
penicillin G, 100 µg/mL streptomycin, 10 mM HEPES, and 2 mM L-glutamine, 208 
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containing 20 U/mL collagenase D and 1 µg/mL DNase I (Roche Diagnostics GmbH, 209 
Mannheim, Germany). After incubation for 60 min at 37 °C with vigorous shaking, cells 210 
were re-suspended in 4 mL 40% (v/v) Percoll (Pharmacia, Uppsala, Sweden) and 211 
layered onto 4 mL 80% (v/v) Percoll. After centrifugation at 600  g for 20 min at 15 °C, 212 
cells at the interface were collected.  213 
Preparation of peritoneal exudate cells: One day after the sensitization, peritoneal 214 
exudate cells were collected by washing the peritoneal cavity with 10 mL cold 10% 215 
FCS RPMI medium as previously described [28]. 216 
Flow cytometric analysis: Lung white blood cells were diluted to a density of 2  217 
105/100 µL, and cultured with 5 ng/mL of phorbol 12-myristate 13-acetate 218 
(Sigma-Aldrich), 500 ng/mL of ionomycin (Calbiochem, San Diego, CA), and 2 µM of 219 
monensin (Sigma-Aldrich) for 4 h at 37 °C before the cell surface was stained. Then, 220 
cells were pre-incubated with anti-FcγRII and III mAb (Clone 93; BioLegend, San 221 
Diego, CA) on ice for 15 min in PBS containing 1% FCS and 0.1% sodium azide, and 222 
stained with Allophycocyanin (APC)/Cy7 or Peridinin-Chlorophyll Protein Complex 223 
(PerCP)-conjugated anti- cluster of differentiation (CD)3 (Clone 17A2; Biolegend), 224 
phycoerythrin (PE) or Fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (Clone 225 
GK1.5; BD Biosciences, San Jose, CA), PerCP-conjugated anti-CD8α (Clone 53-6.7; 226 
Biolegend), and APC-conjugated anti-CD25 (Clone 3C7; Biolegend). Cells were then 227 
incubated in the presence of cytofix/cytoperm (BD Biosciences Pharmingen), washed 228 
twice in BD perm/wash solution and stained with PE-conjugated anti-IL-4 (clone 229 
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11B11; Biolegend), or Foxp3 (Clone FJK-16s; Thermo Fisher Scientific). Cells in 230 
peritoneal lavage fluid were pre-incubated with anti-FcγRII/ III mAb (BioLegend) and 231 
stained with APC-conjugated anti-CD11c (Clone N418; Biolegend), PE-conjugated 232 
anti-I-A/I-E (Clone M5/114.15.2; Biolegend), PE/Cy7-conjugated anti-CD40 (Clone 233 
3/23; Biolegend), FITC-conjugated anti-CD80 (Clone 16-10A1; Biolegend), and 234 
APC/Cy7-conjugated anti-CD86 (Clone GL-1; Biolegend). Dead cells were excluded by 235 
7-AAD staining (Biolegend) and viable cells were gated. The positive populations were 236 
defined based on isotype-matched control IgG for each Ab. Peritoneal dendritic cells 237 
were gated as CD11chigh I-A/I-Ehigh cells. The stained cells were analyzed using a BD 238 
FACSAria II cell sorter (BD Biosciences) or BD FACSCant II flow cytometer (BD 239 
Biosciences).  240 
Cell preparation and stimulation: Bronchial lymph nodes (BLNs) were obtained from 241 
mice one day after OVA challenge as previously described [29]. To evaluate T cell 242 
responses induced by sensitization, spleens were excised from sensitized mice before 243 
OVA inhalation. BLN and spleens were teased apart between two ground glass slides 244 
and washed. BLN cells (4  105 cells/well) were cultured in the presence of 10 μg/mL 245 
OVA for 3 days. Spleen cells (4  105 cells/well) were cultured in the presence of 100 246 
μg/mL OVA for 2 days. 247 
Preparation and culture of dendritic cells: Bone marrow-derived DCs (BM-DCs) were 248 
prepared as described previously [20]. In brief, bone marrow cells from WT mice were 249 
cultured at a density of 2  105 cells/mL in 10 mL RPMI media 1640 supplemented with 250 
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10% FCS, 100 U/mL penicillin G, 100 µg/mL streptomycin, 2 mM L-glutamine, and 50 251 
µM 2-mercaptoethanol, containing 20 ng/mL murine granulocyte-macrophage 252 
colony-stimulating factor (Wako Pure Chemical Industries). On day 8, the non-adherent 253 
cells were harvested and used as BM-DCs. BM-DCs were stimulated at 1  105 254 
cells/mL for 24 h at 37 °C in 5% CO2 with oligonucleotides in the presence of 255 
maturation factors such as IL-1β (10 ng/mL; PeproTech Inc., Rocky Hill, NJ), tumor 256 
necrosis factor-α (50 ng/mL; PeproTech Inc.), and prostaglandin E2 (10
-6 M; 257 
Sigma-Aldrich) for the induction of Th2-oriented immune responses in DCs [30]. 258 
Lipopolysaccharide (LPS) prepared from Escherichia coli O-111 (Sigma-Aldrich) was 259 
used as a control for the stimulation of BM-DCs, and Polymyxin B (Sigma-Aldrich) 260 
was used to neutralize the effects of LPS. 261 
Statistical analysis: Statistical analysis was performed using GraphPad Prism 5 262 
software (GraphPad Software, La Jolla, CA). Differences between two groups were 263 
tested using a two-tailed analysis and an unpaired Student’s t-test. Differences among 264 
three groups or more were tested using ANOVA with a post hoc analysis (Tukey’ 265 




ODN112 attenuates prototypical asthma-related features: Airway hyperresponsiveness 268 
was estimated by maximum values of RL in response to inhaled methacholine or vehicle, 269 
and the change from baseline values of RL. While the lung resistance in response to 270 
vehicle was not significantly different among the groups, the lung resistance in response 271 
to inhaled methacholine one day after OVA inhalation was attenuated by the treatment 272 
with ODN112 and CpG-ODN, whereas ODN112GC did not alter the increased lung 273 
resistance (Fig. 2). ODN112 did not significantly alter the expression of M1 and M3 274 
muscarinic acetylcholine receptors and β2-adrenergic receptors, which are directly 275 
related to airway contraction and relaxation in the lung (Fig. S1). We next evaluated the 276 
effect of ODN treatment on IL-4-directed Ig class switching. The treatment with 277 
ODN112 and CpG-ODN significantly reduced allergen-specific IgE (Fig. 3A) and IgG1 278 
(Fig. 3B) levels in sera compared to those in vehicle-treated mice; however, 279 
ODN112GC did not significantly change the sera levels post OVA inhalation (Fig. 3A 280 
and 3B). 281 
We investigated the effect of ODN112 treatment on eosinophilic inflammation 282 
following allergen challenge by comparing the number of inflammatory cells in BAL 283 
fluid of mice 5 days after OVA challenge. The number of eosinophils in BAL fluid was 284 
significantly lower in mice treated with 10 μg ODN112, 100 μg ODN112, and 285 
CpG-ODN, but not with ODN112GC, than that in mice treated with vehicle. The 286 
number of total cells, mononuclear cells, neutrophils, and lymphocytes did not change 287 
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significantly among each treated-group (Fig. 4A and 4B). In accordance with this 288 
observation, eosinophil infiltration in the peribronchial area was reduced in mice treated 289 
with ODN112 and CpG-ODN, but not with ODN112GC, compared to mice treated with 290 
vehicle (Fig. 4C). Although the eosinophil number in the BAL fluid of 100 μg 291 
ODN112-treated mice was lower than that in mice treated with 10 μg ODN112 (Fig. 292 
4B), red blood cells were observed in the BAL fluid of mice treated with 100 μg 293 
ODN112 (data not shown).  294 
ODN112 attenuates MUC5AC mRNA production but not goblet cell hyperplasia in 295 
asthma: We next evaluated goblet cell hyperplasia in airway epithelial cells in mice at 296 
various time intervals after OVA inhalation. The goblet cell number slightly increased 297 
on day 1, and significantly increased on days 3 and 5 (Fig. 5A). We measured the 298 
number of goblet cells in the airway epithelium on day 5 post OVA inhalation to assess 299 
mucus production by ODN112 treatment during the sensitization phase. Treatment with 300 
CpG-ODN significantly reduced mucus production in asthmatic mice (Fig. 5B). A 301 
similar tendency was observed in mice treated with ODN112, but not ODN112GC, 302 
although the difference between vehicle- and ODN112-treated mice did not reach 303 
significance at the time points examined (Fig. 5B).  304 
MUC5AC mRNA expression in the lung one day after OVA inhalation was 305 
significantly reduced in mice treated with ODN112 and CpG-ODN, but not ODN112GC 306 
(Fig. 5C). MUC5B and MUC2 expression in the lung were not statistically different 307 
between vehicle- and ODN112-treated mice, or vehicle- and ODN112GC-treated mice 308 
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after allergen inhalation (Fig. 5C). CpG-ODN significantly enhanced MUC5B mRNA 309 
expression, but did not alter MUC2 expression in the lung after allergen inhalation (Fig. 310 
5C). Thus, altered MUC5AC and MUC5B levels in mice treated with ODNs may reflect 311 
the histological goblet cell hyperplasia in the airway epithelium. On the other hand, the 312 
volume proportions of collagen fibers in the airway walls of mice treated with ODN112, 313 
ODN112GC, or CpG-ODN were not largely different when compared with the control 314 
group (Fig. 5D). 315 
ODN112 suppresses Th2 cytokine production and enhances IFN-γ production in 316 
lungs and BLN: We further compared Th1 and Th2 cytokine levels in the lung among 317 
ODN-treated mice. ODN112 and CpG-ODN significantly reduced IL-4, IL-5, and IL-13 318 
production in the lung compared with vehicle-treated mice, whereas the treatment with 319 
ODN112GC did not (Fig. 6A). In contrast, treatment with ODN112 and CpG-ODN, but 320 
not ODN112GC, enhanced IFN-γ production in the lung (Fig. 6A). Although the total 321 
number of CD4+ T cells significantly increased in the lung of mice treated with 322 
ODN112 and CpG-ODN (Fig. 6B), the number of IL-4+ CD4+ and IL-4+ CD8+ T cells 323 
was significantly reduced with ODN112 and CpG-ODN one day after OVA inhalation 324 
(Fig. 6C). In contrast, the number of regulatory T cells, defined as CD3+ CD4+ CD25+ 325 
Foxp3 cells, were not significantly different between mice treated with PBS and mice 326 
treated with ODNs (Fig. 6D). In BLN, IL-4, IL-5, and IL-13 were significantly reduced 327 
one day after OVA inhalation in mice treated with ODN112 and CpG-ODN, compared 328 
with vehicle. IFN-γ increased in the BLN of mice treated with ODN112 and CpG-ODN 329 
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compared with vehicle (Fig. 6E). These results suggest that the attenuated Th2 cytokine 330 
production associated with increased IFN-γ in the mice lung treated with ODN112 may 331 
be responsible for the attenuated prototypical asthma-related features. 332 
ODN112 suppresses allergen sensitization: We measured Th2 cytokine production in 333 
the spleen to evaluate the T cell phenotypes produced during the sensitization phase of 334 
ODN treatment. ODN112 and CpG-ODN significantly reduced IL-5 and IL-13 335 
production from splenocytes stimulated with OVA , but not ODN112GC (Fig. 7). IL-4 336 
production from splenocytes was undetectable level (<4 pg/mL, data not shown). In 337 
contrast, ODN112 and CpG-ODN significantly increased IFN-γ production from 338 
splenocytes stimulated with OVA. These results suggest that ODN112 and CpG-ODN 339 
may play an important role in the attenuation of Th2 cytokine production and the 340 
induction of IFN-γ production by modulating Th1/Th2 balance during Th cell 341 
differentiation in allergic sensitization. 342 
ODN112 increases CD40 and CD80 expression, and IL-12p40 production from 343 
DCs:DCs play a key regulatory role in the direction of T cell differentiation through 344 
cytokine production and a specific co-stimulatory molecule expression. Therefore, to 345 
assess the effect of ODN112 on DC phenotype, we evaluated CD40, CD80, and CD86 346 
expression on peritoneal DCs after the treatment and IL-12p40 production from 347 
Th2-oriented DCs stimulated with ODNs. CD40 and CD80 expression on DCs were 348 
significantly increased by the administration of ODN112 or CpG-ODN. In contrast, 349 
CD86 expression on peritoneal DCs were not altered by the co-administration of ODNs 350 
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(Fig. 8A and 8B). ODN112 and CpG-ODN, but not ODN112GC, enhanced IL-12p40 351 
synthesis from Th2-oriented BM-DCs (Fig. 8C). Such enhanced IL-12p40 production 352 
was not affected by the presence of polymyxin B, whereas the LPS-induced IL-12p40 353 
production was significantly reduced in the presence of polymyxin B, suggesting that 354 
the IL-12p40 production after the stimulation with ODN112 or CpG-ODN was not 355 
induced by contaminated LPS in the ODNs (Fig. 8C).Discussion 356 
This study reports the first evidence of a novel eukaryotic TLR9 agonist 357 
containing a non-canonical CpG motif; 5’-GTCGGT-3’, in the suppression of allergic 358 
asthma. In the battle against Cryptococcus infection, the host innate immune system 359 
senses its DNA and induces a Th1 immune response for protection against the infection 360 
[20, 31], whereas the microorganism resists the host innate immune system by inducing 361 
a Th2 immune response to cryptococcal mannoproteins [32] or capsular polysaccharide 362 
glucuronoxylomannan [33]. In the present study, we used ODN112 derived from 363 
cryptococcal DNA as a tool for inducing a Th1 immune response in asthma. The main 364 
features of ODN112 treatment in our study were: suppressed Th2 cytokine production 365 
by ODN112 administration during the sensitization phase; enhanced IFN-γ production 366 
in the lung and BLN after the onset of asthma-related features; significant reduction of 367 
IL-4+ CD4+, and IL-4+ CD8+ T cells in the lung; and attenuated allergen-induced 368 
asthmatic airway responses including airway hyperresponsiveness (AHR), mucus gene 369 
expression, antigen-specific immunoglobulin, and eosinophil accumulation in the 370 
airway. Furthermore, ODN112 also enhanced CD40 and CD80 expression, and 371 
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IL-12p40 synthesis by Th2-oriented DCs. 372 
Enhanced AHR and airway remodeling including an increased volume of the 373 
airway smooth muscle, thickening of the basement membrane, and goblet cell 374 
hyperplasia are responsible for airway narrowing after allergen inhalation [34]. In these 375 
features, ODN112 suppressed AHR, but did not alter the other characteristics of airway 376 
remodeling, as evidenced by: 1) ODN112 attenuated the RL value in response to inhaled 377 
methacholine after OVA inhalation; 2) ODN112 did not alter mRNA levels of M1 and 378 
M3 muscarinic acetylcholine receptors and β2-adrenergic receptors in the lung; and 3) 379 
ODN112 did not histologically alter the volume of collagen and mucus production in 380 
airway. Although further studies are required to determine whether ODN112 attenuates 381 
airway remodeling induced by repeated long-term allergen exposure, since the asthma 382 
mouse model is not sufficient for the evaluation of airway remodeling, our data suggest 383 
that attenuated AHR after treatment with ODN112 may not be attributable for its effect 384 
on relieving histological change of airways after allergen inhalation but rather its 385 
suppressive activity against Th2-type immune response. Therefore, verification of the 386 
treatment effect of ODN112 on the Th1/Th2 balance during the elicitation phase of 387 
asthmatic airway responses is further required. The salient difference between ODN112 388 
and CpG-ODN is in its backbone. CpG-ODN contains a full phosphorothioate backbone, 389 
which prevents its degradation by DNase, thereby increasing the risk of excess 390 
immunological responses in vivo [15]. In contrast, the backbone of ODN112 is not 391 
modified because a phosphorothioate backbone completely abolished its effect on DC 392 
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activation [21]. This feature might reduce the risk of excess immunological response. 393 
We found that ODN112 treatment with a dose 10 times higher than CpG-ODN is needed 394 
for similar suppressive effects on the eosinophil count in BAL fluid, suggesting that 395 
unmodified ODN112 may be easily degraded in vivo. Furthermore, we previously 396 
showed that the concentration of IL-12p40 in the culture supernatant of BM-DCs 397 
stimulated with 30 µg/ml ODN112 was two times lower than that in the culture 398 
supernatant of BM-DCs stimulated with 1 µg/ml CpG-ODN [21]. Although the data 399 
regarding whether ODN112 is generally a weaker stimulator for TLR9 than sCpG-ODN 400 
are not adequately accumulated, the potency of ODN112 as a stimulator for TLR9 might 401 
be approximately 10 to 60 times lower than that of CpG-ODN. Further research 402 
regarding its delivery system and the degree of DNase resistance required for ODN112 403 
stability in vivo are required. Horner et al. showed that ISS-ODN conjugated allergen 404 
was more effective in inducing Th1-type immune response than ISS-ODN mixed with 405 
allergen [35]. Encapsulating and sealing ISS-ODN inside nanoparticles may be also an 406 
effective method to protect ODN against break down by DNases [36]. Thus, improving 407 
intracellular delivery and binding of ODN112 with allergen are necessary to improve its 408 
efficacy as a Th1-inducing adjuvant in asthma treatment. 409 
The sequence in ODN112 that differs from the CpG motif is unique and 410 
responsible for the suppression of asthmatic features in mice. Regarding the role of 411 
non-canonical CpG motif in the anti-Th2 immune response, Iliev et al. have showed that 412 
the genomic DNA of Lactobacillus rhamnosus GG with a core sequence of TTTCGTTT 413 
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motif potentially suppressed the OVA-specific IgE production in mice through 414 
TLR9-dependent activation of DCs and induction of IFN-γ production by CD4+ T cells 415 
[37]. In contrast, ISS-ODN containing a unique core sequence, 5’-ATTTTTAC-3’ and a 416 
six-base secondary loop structure, in L. gasseri JCM1131 genome enhanced 417 
immunostimulatory activity such as IL-12p70 and IFN-γ production in human 418 
peripheral blood mononuclear cells [38]. In the present study, ODN112 lacks canonical 419 
CpG motifs, but contains a unique core sequence, 5’-GTCGGT-3’. In particular, a 420 
cytosine-guanine (CG) in the 6-base fragment in ODN112 is key for the anti-allergic 421 
activity, although we could not rule out the possibility that the secondary loop structure 422 
of ODN112 might also play an important role in the induction of Th1 immunity in 423 
asthma. Within further limitation of the present study, we could not completely rule out 424 
the possibility of the involvement of other pathogen recognition receptors in the 425 
recognition of 5’-GTCGGT-3’ because we could not use TLR9KO mice in the present 426 
study. However, the results from the in vitro experiment strongly suggest that 427 
stimulatory activities of ODN112 are TLR9 dependent [21]. 428 
The suppressive effect of ODN112 on allergen sensitization implies the 429 
preventative effect of ODN112 on the development of Th2 cells in asthma. Dendritic 430 
cells (DCs), the most proficient antigen presenting cells, play a critical role in adaptive 431 
immune responses by priming Th2 cells to respiratory allergens, which is a critical step 432 
for the development and exacerbation of allergic asthma [39]. Sustained IL-12 signaling 433 
induces STAT4 activation in T cells, which skew naive Th cells toward the Th1 434 
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phenotype as defined by IFN-γ expression [40, 41]. IFN-γ antagonizes the development 435 
of Th2 cells and also converts fully polarized Th2 cells into IFN-γ-producing Th1 cells 436 
by transduction of T-bet [42]. We showed that ODN112 significantly increased 437 
IL-12p40 production from both Th2-oriented DCs and immature DCs in our present and 438 
previous studies [21]. In the present study, although IL-12p40 and IFN-γ in the 439 
peritoneal lavage fluids at one day and three days after sensitization were undetectable 440 
(<15 pg/mL, data not shown), the costimulatory molecular expression pattern of CD80 441 
on peritoneal DCs following sensitization indicates that ODN112 and CpG-ODN 442 
induces the Th1-inducing capacity in Th2-biased DCs [43]. In addition, upregulation of 443 
CD40 and IL-12 may synergistically enhance IFN-γ production by T cell 444 
receptor-stimulated T cells [44]. Several factors involved in the induction co-stimulatory 445 
molecule expression on antigen presenting cells are reported. Previously, it is 446 
demonstrated that IL-4 is an important cytokine for CD86 expression on macrophages 447 
[45]. In contrast, IFN-γ upregulates CD40 and CD80 in monocytes [46]. Furthermore, 448 
TLR agonists themselves, such as ODNs and LPS, induce co-stimulatory molecule 449 
expression on DCs [47]. Therefore, our data suggest that the Th1-type cytokine milieu 450 
regulated by ODNs is responsible for enhanced CD40/CD80 expression on DCs in the 451 
peritoneal cavity at the timing of sensitization. The enhanced IFN-γ production, as well 452 
as the reduced Th2 cytokine production, was observed in the spleen of ODN112-treated 453 
mice before allergen inhalation. This suggests that ODN112 redirects immune responses 454 
from Th2 to Th1 during sensitization by changing the DC phenotype, which exhibits the 455 
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suppressed prototypical asthma-related features after allergen inhalation. In clinical 456 
settings, the reduced allergen-induced Th1 response is an important factor related to 457 
ongoing severe atopic asthma [48]. In patients with allergic asthma, blood IL-12 levels 458 
are lower than healthy controls, which is associated with reduced IL-12-dependent 459 
IFN-γ production [49]. In addition, normalization of IFN-γ responses is important for 460 
resolution of inflammation in asthma [48].  461 
In summary, our results indicate that the CD40/CD80/IL-12/IFN-γ axis 462 
activation induced by ODN112 during the sensitization phase suppressed asthmatic 463 
immune responses in the lungs followed by AHR after the development of asthma. Also, 464 
our data suggest the possibility that suppressive activity of ODN112 on Th2 cell 465 
differentiation in the sensitization phase maintains a long-term effect into the elicitation 466 
phase, which may not only be a benefit for the prevention of asthma onset, but also for 467 
the prevention of asthma exacerbation.  468 
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Figure legends 647 
Figure 1. Schematic figure illustrating the experimental design of the study. Mice 648 
were sensitized with intraperitoneal injections of OVA and ODNs adsorbed with 649 
aluminum hydroxide on days 0 and 5. On day 26, mice were challenged with 650 
aerosolized OVA for 1 h on two occasions, 4 h apart. The phenotype of the DCs in the 651 
peritoneal cavity and the cytokine production from splenocytes were evaluated on days 652 
6 and 17, respectively. After the OVA inhalation, lung resistance, and cytokine levels in 653 
the lung and BLN were evaluated on day 27. On day 31, asthma related features such as 654 
Ig levels in sera, eosinophil counts in BAL fluids, and lung histology in mice treated 655 
with PBS or ODNs were evaluated. ▲, time points of sensitization or inhalation; Δ, 656 
time points of sampling of specimen. 657 
Figure 2. ODN112 reduces lung resistance in asthmatic mice. The lung resistance was 658 
estimated by maximum values of RL in response to inhaled methacholine or vehicle 659 
(left), and the change from baseline values of RL in response to methacholine (right) in 660 
mice treated with vehicle or 10 µg ODNs were measured one day after OVA challenge. 661 
Data are shown as the mean ± SEM based on at least three independent experiments (n 662 
= 5–14). Δ, vehicle-treated mice; ○, ODN112-treated mice; ●, ODN112GC-treated 663 
mice; □, CpG-ODN-treated mice. * p < .05, ** p < .01 compared to vehicle-treated 664 
mice; NS, not significant.  665 
Figure 3. ODN112 attenuates antigen specific Th2-type immunoglobulin production 666 
in asthmatic mice. Sera were collected from mice treated with vehicle or 10 µg ODNs, 667 
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5 days after OVA challenge. OVA specific IgE (A) and IgG1 (B) levels in sera were 668 
measured by ELISA. Data are shown as the mean ± SEM based on two to three 669 
independent experiments (n = 11–13). * p < .05 compared to vehicle-treated mice. 670 
Figure 4. ODN112 attenuates eosinophilic infiltration in the lung of asthmatic mice. 671 
BAL and lung samples were collected on day 5 after OVA inhalation from mice treated 672 
with vehicle or 10 µg or 100 µg of ODNs. Cells in the BAL fluid were stained with 673 
Diff-Quick solution, and cell composition was determined under light microscopy. (A) 674 
Representative microscope photograph of cells in the BAL fluid of mice (original 675 
magnification  1000). (B) Cell composition in BAL fluid of mice. (C) The number of 676 
eosinophils per square millimeter closely surrounding the bronchi in mice. Data are 677 
shown as the mean ± SEM (n = 6–13 mice/group). * p < .05, ** p < .01 compared to 678 
vehicle-treated mice. NS, not significant. 679 
Figure 5. ODN112 attenuates MUC5AC expression in the lung, but not the 680 
percentage of goblet cells in epithelial cells. (A) The lungs were excised from mice 681 
following OVA challenge. The percentage of goblet cells were evaluated by the 682 
proportion of PAS-positive cells in the total airway epithelium of the bronchioles 683 
Photomicrographs were taken at  400. Data are shown as the mean ± SEM of five 684 
random bronchioles in the three lung sections from each mouse (n = 4/group). (B) The 685 
lungs were collected from mice treated with vehicle or 10 µg ODNs 5 d after OVA 686 
challenge. The percentage of goblet cells in mice treated with 10 µg ODNs were 687 
compared to that in mice treated with vehicle. The photomicrographs were taken at  688 
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400. Data are shown as the mean ± SEM of five random bronchioles in the three lung 689 
sections from each mouse (n = 9/group). (C) The lung was collected from mice treated 690 
with vehicle or 10 µg ODNs 24 h after OVA challenge. Gene expression levels were 691 
measured by quantitative reverse transcription-PCR. Data are shown as the mean ± 692 
SEM of 4 mice. Experiments were repeated twice with similar results. (D) The volume 693 
of collagen fibers in the airway wall were evaluated by Masson’s trichrome staining. 694 
Representative microscope photographs (original magnification  400) of the staining 695 
are shown (n = 4/group). Experiments were repeated twice with similar results. # p 696 
< .05 compared to the levels before OVA inhalation. * p < .05, ** p < .01 compared to 697 
vehicle-treated mice. NS, not significant. 698 
Figure 6. ODN112 attenuates Th2 cytokine production and enhances IFN-γ 699 
production in the lung and bronchial lymph nodes. (A) The entire lungs from mice 700 
treated with vehicle or 10 µg ODNs were excised one day after OVA inhalation and 701 
homogenized. Cytokine levels in the lung were measured by ELISA. The number of 702 
CD4+ T cells in the lung (B), representative profiles and the percentage of IL-4 703 
producing T cells in T cells (C), and the number of regulatory T cells in the lung (D) 704 
were assayed by flow cytometry. Data are shown as the mean ± SEM based on 4 to 13 705 
mice. (E) BLN cells were prepared from mice treated with vehicle or 10 µg ODNs one 706 
day after OVA challenge and stimulated with 10 μg/mL of OVA for 3 days. Cytokine 707 
levels in the culture supernatants were measured by ELISA. Data are shown as the mean 708 
± SD based on triplicate cultures. Experiments were repeated twice with similar results. 709 
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* p < .05, ** p < .01 compared to vehicle-treated mice. 710 
Figure 7. ODN112 attenuates Th2 cytokine production, and enhances IFN-γ 711 
production in the spleen. Mice were sensitized with OVA and aluminum hydroxide in 712 
the presence of vehicle or 10 µg ODNs. Twelve days after sensitization, splenocytes 713 
were prepared from each mouse and stimulated with 100 μg/mL of OVA for 2 d. 714 
Cytokine levels in the culture supernatants were measured by ELISA. Data are shown as 715 
the mean ± SD based on triplicate cultures. Experiments were repeated twice with 716 
similar results. * p < .05, ** p < .01 compared to vehicle-treated mice. 717 
Figure 8. ODN112 increases IL-12p40 production from Th2-oriented DCs. Mice were 718 
sensitized with OVA and aluminum hydroxide in the presence of vehicle or 10 µg ODNs. 719 
Peritoneal lavage fluid was collected one day after the sensitization, and the mean 720 
fluorescent intensity of CD40, CD80, and CD86 on DCs was determined by flow 721 
cytometry analysis. (A) Representative profiles of costimulatory molecules on 722 
peritoneal dendritic cells. (B) Mean fluorescence intensity (MFI) of costimulatory 723 
molecules were analyzed in each group. Data are shown as the mean ± SD of 3 mice. 724 
(C) Bone marrow derived DCs were cultured with maturation factors and vehicle or 725 
ODNs in the presence or absence of polymyxin B. IL-12p40 level in the culture 726 
supernatants was measured by ELISA. Data are shown as the mean ± SD based on 727 
triplicate cultures. Experiments were repeated twice with similar results. ■, the cultures 728 
in the absence of PL-B; □, the cultures in the presence of polymyxin B. * p < .05, **, p 729 
< .01; NS, not significant.  730 
38 
 
Supplementary Figure legends 731 
Figure S1. ODN112 does not alter receptor expression levels associated with airway 732 
hyper responsiveness. The entire lungs were excised from mice treated with vehicle or 733 
ODNs one day after OVA inhalation. The expression levels of Chrm2, Chrm3, and 734 
Adrb2 were measured by quantitative reverse transcription-PCR. Data are shown as the 735 
mean ± SEM based on three to six mice. Experiments were repeated twice with similar 736 
results. NS, not significant. 737 
Figure 1.  Okuyama et al.
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Figure 7.  Okuyama et al.























































































































































































Table 1. Sequences of synthesized ODNs























































Supplementary Table 1. Primer sequences for RT-PCR
Gene
(Gene products)
Muc5ac forward: 5’- ACACCGCTCTGATGTTCCTCACC -3’
(mucin 5, subtypes A and C, tracheobronchial/gastric) reverse: 5’- ATGTCCTGGGTTGAAGGCTCGT -3’
Muc5b forward: 5’- GGATGGGCAGCAGAAACTGGA -3’
(mucin 5, subtype B, tracheobronchial) reverse: 5’- GACAGTGATAGGTGGGATGAAGGTG -3’
Muc2 forward: 5’- CAAATCAGGTGGCAGTGTGTTGCT -3’
(mucin 2) reverse: 5’- TGGTAGGAGGAGGGTTGGAAGATG -3’
Chrm2 forward: 5’- AGCCAGACTCCACCAGATCG -3’
(AChR-M2) reverse: 5’- AGCCAAACCATTGTTCGAGGAG -3’
Chrm3 forward: 5’- TCCCTGCTGCGAGAGACCG -3’
(M3R) reverse: 5’- GAAGTAGATGCCATTGCTGGTCA -3’
Adrb2 forward: 5’- TTGGCAACTTCTGGTGCGAG -3’
(Adrb-2) reverse: 5’- AGCGATCCACTGCAATCACG -3’
Hprt forward: 5’- TTGGGCTTACCTCACTGCTTTCC -3’
(HPRT) reverse: 5’- ATCATCGCTAATCACGACGCTGG -3’
HPRT: hypoxanthine-guanine phosphoribosyltransferase.
Primer sequences
